| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
As a Vitamin K analog, Vitamin K4 targets the same pathway as other K vitamins. It serves as a precursor to menaquinone (Vitamin K2) in the body, which is an essential cofactor for the enzyme γ-glutamyl carboxylase. This enzyme is responsible for the post-translational carboxylation of glutamate residues on several proteins, including the coagulation factors II, VII, IX, X, and proteins C and S, which is critical for their biological activity.
|
|---|---|
| ln Vitro |
In vitro, Vitamin K4 has demonstrated anti-cancer functionality. Studies have shown that it induces apoptosis in prostate carcinoma cells. It inhibits the proliferation of PC3 prostate cancer cells with an IC₅₀ of 20.94 µM. At concentrations of 20 and 40 µM, it induces cell cycle arrest at the S phase and mitochondrial apoptosis in these cells.
|
| ln Vivo |
In vivo, as a Vitamin K analog, Vitamin K4 would be expected to support normal blood coagulation and bone metabolism. Its primary role is to ensure the proper functioning of the coagulation cascade. However, its specific effects in vivo are less well-characterized compared to other Vitamin K forms, as it is often used as a stable precursor.
|
| Enzyme Assay |
In vitro binding assays for Vitamin K4 are not standard, as it acts as a cofactor rather than a direct receptor ligand. However, its activity can be assessed in a functional assay measuring the γ-carboxylation of a peptide substrate by γ-glutamyl carboxylase. The enzyme is incubated with the substrate, Vitamin K4, and other cofactors, and the degree of carboxylation is measured to assess the compound's activity.
|
| Cell Assay |
In vitro cell-based assays for Vitamin K4 have been performed on cancer cell lines like PC3 prostate cancer cells. Cells are treated with varying concentrations of Vitamin K4 (e.g., up to 40 µM) for a defined period. Cell proliferation is then measured using assays like MTT, and apoptosis is assessed by measuring caspase activity or by flow cytometry after Annexin V/PI staining.
|
| Animal Protocol |
In vivo animal studies for Vitamin K4 would typically involve using a rat model of Vitamin K deficiency. Animals are fed a Vitamin K-deficient diet and then administered Vitamin K4 to assess its ability to restore normal blood coagulation, measured by the prothrombin time (PT). However, specific protocols are not detailed in the provided literature.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Vitamin K4 are not extensively detailed in the provided literature. As a Vitamin K analog, it is likely to be absorbed from the gastrointestinal tract and transported to the liver, where it is converted to its active hydroquinone form. It is a synthetic compound intended for research use.
|
| Toxicity/Toxicokinetics |
As a synthetic Vitamin K, Vitamin K4 is generally well-tolerated at therapeutic doses. However, high doses of Vitamin K analogs can cause toxicity. The compound is not intended for human or veterinary use. Safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Acetomenaphthone is a type of naphthalene compound.
Vitamin K4 is a synthetic and chemically stable form of Vitamin K. It is also known as Acetomenaphthone and Menadiol Diacetate. It is used as a research tool to study Vitamin K biology and as a potential anti-cancer agent. This product is for research use only. |
| Molecular Formula |
C15H14O4
|
|---|---|
| Molecular Weight |
258.2693
|
| Exact Mass |
258.089
|
| CAS # |
573-20-6
|
| PubChem CID |
11310
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
388.9±30.0 °C at 760 mmHg
|
| Melting Point |
113 °C
|
| Flash Point |
195.1±23.0 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.580
|
| LogP |
2.67
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
352
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])[H])=O)C1=C(C([H])([H])[H])C([H])=C(C2=C([H])C([H])=C([H])C([H])=C21)OC(C([H])([H])[H])=O
|
| InChi Key |
RYWSYCQQUDFMAU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14O4/c1-9-8-14(18-10(2)16)12-6-4-5-7-13(12)15(9)19-11(3)17/h4-8H,1-3H3
|
| Chemical Name |
1,4-Naphthalenediol, 2-methyl-, diacetate
|
| Synonyms |
Vitamin K4 (VK4); Acetomenaphthone; NSC 403062; NSC-403062; NSC403062
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~387.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8719 mL | 19.3596 mL | 38.7192 mL | |
| 5 mM | 0.7744 mL | 3.8719 mL | 7.7438 mL | |
| 10 mM | 0.3872 mL | 1.9360 mL | 3.8719 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02309489 | COMPLETEDWITH RESULTS | Behavioral: Partner involvement | Postpartum Period | London School of Hygiene and Tropical Medicine | 2015-01 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA